GEMS: A CRISPR Epigenetics Platform to Revolutionise Genetic Medicine

Time: 1:30 pm
day: Day 1 Track A PM

Details:

• Enabling in vivo gene therapy with a hypercompact platform, dCas proteins, epigenetic modulators, and guides
• Durable gene suppression and activation after transient GEMS expression
• A de-risked platform for in vivo gene therapy: FSHD

Speakers:

Dan Hart Daniel Hart, Ph.D., is Head of Technology Development at Epicrispr Bio. Dr. Hart completed postdoctoral training in the laboratory of Michael R. Green at the Read more